Diseases Associated with Defects in Vitamin B6 Metabolism or Utilization

Merrill, and A H; Henderson, J. Michael

doi:10.1146/annurev.nu.07.070187.001033

Cited by 97 publications

(43 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A possible explanation could be that plasma PLP is bound to serum albumin while being transported by the blood; however, low serum albumin in our critically ill patients caused the dephosphorylation of plasma PLP into PL (Merrill and Henderson, 1987).…”

Section: Discussionmentioning

confidence: 85%

Vitamin B6 supplementation increases immune responses in critically ill patients

Cheng

Chang²,

Lee

et al. 2006

Eur J Clin Nutr

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 85%

Vitamin B6 supplementation increases immune responses in critically ill patients

Cheng

Chang²,

Lee

et al. 2006

Eur J Clin Nutr

View full text Add to dashboard Cite

“…Erythrocyte PLP status should be considered when assessing vitamin B6 status in the critically ill. Pyridoxal 5'-phosphate and PL are both bound to serum albumin, with the PLP binding more tightly, against rapid hydrolysis by alkaline phosphatase while being transported by the blood. Lower serum albumin levels in our critically ill patients may lead to the dephosphorylation of plasma PLP into PL (Merrill & Henderson, 1987). Because dietary vitamin B6 and protein intake as well as plasma alkaline phosphatase activity may affect plasma PLP concentration, recent research has suggested that plasma PL may be useful as an indicator for vitamin B6 status (Leklem, 1990).…”

Section: Discussionmentioning

confidence: 99%

Vitamin B6 intakes and status of mechanically ventilated critically ill patients in Taiwan

Huang¹,

Ph²,

Chen³

et al. 2002

Eur J Clin Nutr

View full text Add to dashboard Cite

Objective: To assess vitamin B6 intake and status of critically ill patients. The relationship between vitamin B6 status indicators and the severity of illness and outcome in these patients was also examined. Design: Prospective clinical study. Setting: The study was performed at the Taichung Veteran General Hospital, in the central part of Taiwan. Subjects: Ninety-four patients in the intensive care unit (ICU) entered the study and 46 patients successfully completed this study. Interventions: No intervention. Main outcome measures: Vitamin B6 intake was recorded for 14 days. Vitamin B6 status was assessed by direct measures (plasma pyridoxal 5 0 -phosphate (PLP), pyridoxal (PL), and urinary 4-pyridoxic acid (4-PA)) and indirect measures (erythrocyte alanine (EALT-AC) and aspartate (EAST-AC) aminotransaminase activity coefficient). The severity of illness (APACHE II score), the length of ventilation dependency, and the length of ICU and hospital stay were recorded. Results: Patients had an adequate mean vitamin B6 intake (16.26 AE 19.39 mg) during the 14 day study. Mean vitamin B6 intake was significantly higher on day 14 than on day 1 (P < 0.001). However, plasma PLP and PL concentrations significantly decreased at the 14th day after admission (P < 0.05). Erythrocyte alanine aminotransaminase activity coefficient and EAST-AC did not change significantly. Urinary 4-PA significantly increased at the 14th day (P < 0.001). No significant relationships were found between APACHE II scores and clinical outcomes (the length of ICU and hospital stay, the length of ventilation dependency) of patients, vitamin B6 intake or status indicators. Conclusions: Critically ill patients received nutritional support in the ICU, and had sufficient mean vitamin B6 intake and adequate vitamin B6 status. Therefore, the severity of illness and the results should not be affected by vitamin B6 status. However, we have noted that plasma PLP and PL concentrations significantly decreased while vitamin B6 intake significantly increased on day 14. Critical clinical conditions and complex metabolism in the critically ill may account for the reduction of plasma PLP and PL. Since vitamin B6 deficiency causes profound effects on immune system function, dietary or supplemented vitamin B6 intake is suggested for hospitalized patients.

show abstract

“…PN therapy is frequently recommended for various conditions, including genetic disorders, such as cystathioninuria and homocystinuria, and a range of other disorders, such as premenstrual tension, seizures, carpal tunnel syndrome, and the nausea and vomiting that can occur during pregnancy (1,3,(21)(22)(23). Because it is considered a safe compound, very high doses of B 6 [Ͼ2000-fold higher than the recommended dietary allowance (1.4 -2.1 mg/day, depending on sex and age)] are used in some circumstances (7,24 ).…”

mentioning

confidence: 99%

Plasma Vitamin B6 Vitamers before and after Oral Vitamin B6 Treatment: A Randomized Placebo-controlled Study

Bor

Refsum²,

Bisp

et al. 2003

Clinical Chemistry

View full text Add to dashboard Cite

show abstract

Diseases Associated with Defects in Vitamin B6 Metabolism or Utilization

Cited by 97 publications

References 90 publications

Vitamin B6 supplementation increases immune responses in critically ill patients

Vitamin B6 supplementation increases immune responses in critically ill patients

Vitamin B6 intakes and status of mechanically ventilated critically ill patients in Taiwan

Plasma Vitamin B6 Vitamers before and after Oral Vitamin B6 Treatment: A Randomized Placebo-controlled Study

Contact Info

Product

Resources

About